Kanuma Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to lack of effective lal-d treatments, historical liver disease complications, early orphan drug approvals, limited awareness of lal-d, specialist centered care delivery.

The growth in the forecast period can be attributed to expansion of newborn screening programs, advancements in recombinant enzyme technology, rising rare disease awareness, improved access to specialty care, increased healthcare funding for orphan therapies. Major trends in the forecast period include expansion of enzyme replacement therapies, rising focus on lipid metabolism disorders, growth in pediatric rare disease treatment, improved long term disease management, increasing early diagnosis of lal-d.

The increasing prevalence of lysosomal acid lipase deficiency (LAL-D) is expected to drive the growth of the Kanuma market in the future. LAL-D is a rare genetic disorder that causes the accumulation of lipids in organs, leading to liver dysfunction, cardiovascular issues, and metabolic disturbances. The rising prevalence of LAL-D is primarily due to improved diagnostic techniques and increased awareness, which have led to better detection of this rare genetic disorder. Kanuma is used to treat LAL-D by replacing the deficient enzyme, which helps reduce lipid accumulation and prevent further organ damage. For example, in March 2023, a report from the National Institutes of Health, a U.S.-based health research agency, indicated that the estimated disease prevalence of LAL-D ranges from 1 in 40,000 to 1 in 300,000, depending on ethnicity and geographical location. As a result, the growing prevalence of LAL-D is contributing to the expansion of the Kanuma market.

The rise in healthcare expenditure is also expected to fuel the Kanuma market moving forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal healthcare, preventive services, and public health activities aimed at improving health outcomes over a specific period. The increase in healthcare expenditure is driven by factors such as an aging population, the prevalence of chronic diseases, advances in medical technology, high drug prices, inefficient payment models, and a growing demand for services. In the case of Kanuma, healthcare expenditure includes costs related to enzyme replacement therapy, such as the price of the drug, administration, and ongoing patient monitoring. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, a significant increase compared to the 0.9% growth seen in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. As a result, the rise in healthcare expenditure is contributing to the growth of the Kanuma market.

A key trend in the Kanuma market is the growing focus on enzyme replacement therapy (ERT) to gain a competitive edge in the industry. ERT, including Kanuma, works by replacing the deficient lysosomal acid lipase enzyme, which helps reduce lipid accumulation in organs and alleviates the severe complications associated with lysosomal acid lipase deficiency (LAL-D). For example, in November 2023, the UK-based National Health Service (NHS) announced that sebelipase alfa (Kanuma), as an ERT, would be the first treatment available for Wolman disease, a rare and fatal genetic condition affecting babies and toddlers. This development followed a commercial deal between NHS England and a recommendation from the National Institute for Health and Care Excellence (NICE).

Major companies operating in the kanuma market are AstraZeneca PLC.

North America was the largest region in the kanuma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kanuma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kanuma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the kanuma market by increasing costs associated with enzyme production, bioprocessing equipment, and temperature controlled distribution. These impacts are most significant in hospital and specialty clinic segments across regions reliant on imported enzyme replacement therapies. Higher tariffs can affect affordability and continuity of long term treatment for rare metabolic disorders. However, tariffs are also supporting localized enzyme manufacturing, regional supply chain resilience, and investments in domestic biologics infrastructure.

The kanuma market research report is one of a series of new reports that provides kanuma market statistics, including kanuma industry global market size, regional shares, competitors with a kanuma market share, detailed kanuma market segments, market trends and opportunities, and any further data you may need to thrive in the kanuma industry. This kanuma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kanuma (sebelipase alfa) is a recombinant enzyme replacement therapy used to treat lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder. LAL-D causes the accumulation of lipids in tissues, leading to liver damage, cardiovascular issues, and other complications. Kanuma works by replacing the deficient LAL enzyme, allowing for the breakdown of lipid deposits in the body.

The primary indications for Kanuma are the treatment of lysosomal acid lipase deficiency and its associated conditions. The treatment of LAL-D typically involves enzyme replacement therapy (ERT), such as Kanuma, to replace the deficient lysosomal acid lipase enzyme. The formulations available are injectable formulations and lyophilized powders for reconstitution. Kanuma is used by a wide range of patient demographics, including pediatric, adult, and geriatric patients. It is distributed through various channels, including direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. The drug is utilized by different end users, such as hospitals, specialty clinics, home healthcare providers, and research institutions.

The kanuma market consists of sales of single-dose vials, intravenous infusion solutions, and ready-to-use formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.